“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like NYC Startup Syntimmune Names Former Biogen Exec as New CEO January 2, 2018 Triumvira Names a New CEO January 3, 2018 Adaptimmune Sees Positive Early Results in Cancer Treatment March 15, 2018
